Somatic mosaicism in skin fragility disorders: mechanisms and therapeutic perspectives

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004362

Enrollment

Registered

2013-06-24

Start date

2013-05-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidermolysis bullosa Q81

Interventions

Group 1: Patients with epidermolysis bullosa will be examined in the Department of Dermatology, University Medical Center Freiburg. For diagnostic purposes a skin biopsy will be attained. Further, pat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with epidermolysis bullosa

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Better understanding of revertant mosaicism	—

Secondary

Measure	Time frame
To be able to develop therapy approaches for patients with epidermolysis bullosa based on revertant skin cells	—

Countries

Germany

Contacts

Public ContactDimitra Kiritsi

Klinik für Dermatologie und Venerologie

dimitra.kiritsi@uniklinik-freiburg.de0761-27017010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026